Apoptotic response of malignant rhabdoid tumor cells by Nocentini, Silvano
BioMed  Central
C
TIONAL INTERNA
CANCER CELL
Page 1 of 11
(page number not for citation purposes)
Cancer Cell International
Open Access Primary research
Apoptotic response of malignant rhabdoid tumor cells
Silvano Nocentini*
Address: UMR 218 CNRS, Institut Curie, Institut Curie – Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
Email: Silvano Nocentini* - Silvano.Nocentini@curie.fr
* Corresponding author    
Abstract
Background: Malignant rhabdoid tumors (MRTs) are extremely aggressive and resist current
radio- and chemotherapic treatments. To gain insight into the dysfunctions of MRT cells, the
apoptotic response of a model cell line, MON, was analyzed after exposure to several genotoxic
and non-genotoxic agents employed separately or in association.
Results:  Fluorescence microscopy of chromatin morphology and electrophoretic analysis of
internucleosomal DNA fragmentation revealed that MON cells were, comparatively to HeLa cells,
resistant to apoptosis after treatment with etoposide, cisplatin (CisPt) or X-rays, but underwent
some degree of apoptosis after ultraviolet (UV) C irradiation. Concomitant treatment of MON
cells with X-rays or vinblastine and the phosphatidylinositol 3-kinase (PI3-K) inhibitor wortmannin
resulted in synergistic induction of apoptosis. Western blot analysis showed that the p53 protein
was upregulated in MON cells after exposure to all the different agents tested, singly or in
combination. In treated cells, the p53 downstream effectors p21WAF1/CIP1, Mdm2 and Bax were
induced with some inconsistency with regard to the accumulation of p53. Poly ADP-ribose
polymerase (PARP) cleavage, indicative of ongoing apoptosis, occurred in UVC-irradiated cells and,
especially, in cells treated with combinations of X-rays or vinblastine with wortmannin. However,
there was moderate or no PARP cleavage in cells treated with CisPt, X-rays, vinblastine or
wortmannin singly or with the combinations X-rays plus CisPt or vinblastine and CisPt plus
vinblastine or wortmannin. The synergistic effect on the induction of apoptosis exerted by some
agent combinations corresponded with synergy in respect of MON cell growth inhibition.
Conclusion: These results suggest abnormalities in the p53 pathway and apoptosis control in MRT
cells. The Ras/PI3-K/AKT signaling pathway might also be deregulated in these cells by generating
an excess of survival factors. These dysfunctions might contribute to the resistance of MRTs to
current antineoplastic treatments and could warrant consideration in the search of new
therapeutic approaches.
Background
MRTs occur during early childhood in soft tissues, espe-
cially kidney and the central nervous system [1]. Progno-
sis is poor because of the high cellular proliferation rate,
propensity to metastasis and marked resistance to current
radio- and chemo-therapeutic interventions [2–5].
According to cytogenetic and molecular analyses, MRTs
are generally caused by biallelic alterations of the hSNF5/
INI1 gene [6]. This gene encodes a member of the chro-
matin-remodeling SWI/SNF multiprotein complexes that
activate or repress transcription of target genes [7,8]. SWI/
SNF activity is also required for Rb-dependent
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transcriptional repression and subsequent inhibition of
proliferation [9]. Moreover, the hSNF5/INI1 protein
directly co-operates with several important cellular fac-
tors: c-Myc [10], Gadd34 [11] and ALL-1 [12].
Overexpression of c-Myc, a nuclear phosphoprotein that
regulates DNA replication and cell division, is a consistent
characteristic of rhabdoid cells [13–16]. IGF-II, IGF-IR
and IGF-IIR, which promote cell proliferation and DNA
synthesis through an autocrine mechanism, are also con-
stitutively expressed in several MRT cells lines [17]. High
levels and unusual distribution of p53 protein have been
observed, suggesting some abnormalities in p53 status,
but there is little Mdm2 mRNA expression [16]. However,
p53 protein and the downstream effectors, p21WAF1/
CIP1and Mdm2 were up-regulated by DNA-damaging
drugs and the p53 pathway was considered to be func-
tional [18]. There appear to be no rearrangements or
amplifications in Myc, Ras, Erb B-2 and p53 genes in these
cells [19].
Transfection experiments have shown that when hSNF5/
INI1 protein is re-introduced into cells derived from
MRTs, it inhibits the entry into S-phase [20], prevents cell
proliferation, causes flat cell formation, and directly
represses cyclin D1 gene [21]. Moreover, hSNF5/INI1
overexpression induced apoptosis in two of the three cell
lines tested [22].
The aim of the present study was to gain further insight
into the dysfunctions of MRT cells. A model cell line,
MON, was evaluated in terms of its responses to the gen-
otoxic and non-genotoxic stresses induced by physical
and chemical agents with different modes of action,
employed singly or in association. The treatments pro-
voked different kinds of DNA (and protein) damage (sin-
gle and double strand breaks, oxidation, alkylation,
crosslinks etc.), or interfered with cellular signaling func-
tions. Results showed (a) that MON cells may have
impaired control of apoptosis and (b) that apoptosis can
be strongly activated by inhibition of the PI3-K pathway
under particular stress conditions.
Results
Apoptosis in response to different genotoxic and non-gen-
otoxic stresses was assessed by monitoring the appearance
of typical nuclear morphological changes and internucle-
osomal DNA cleavage, and by investigating some steps in
the apoptotic pathway at the molecular level.
Apoptotic response
In Fig. 1 the responses of MON and HeLa cells are com-
pared. As appraised by morphological criteria such as
chromatin condensation and fragmentation, the rhab-
doid cells were largely refractory to the induction of apop-
tosisafter exposure to etoposide (up to 40 µM, for 2 h),
CisPt (up to 40 µM, for 2 h) and X-rays (up to 10 Gy).
However, they showed some degree of apoptosis follow-
ing UVC irradiation (20 J/m2). All these agents damaged
DNA, directly or indirectly. Etoposide complexes with
topoisomerase II and DNA to enhance double-strand and
single-strand cleavage; CisPt forms adducts with the DNA
dinucleotide d(pGpG) inducing intrastrand and inter-
strand crosslinks; X-rays produce single- and double-
strand breaks and base modifications; UVC radiation
mainly induces pyrimidine-pyrimidine dimers and 6–4
photoproducts. In contrast, HeLa cells showed significant
or high levels of apoptosis in response to all treatments,
even when lower drug concentrations or doses were used.
It is worth noting that the doubling times of MON and
HeLa cells were similar (around 24 h in the conditions
used). Very few cells in either line showed a normal
nuclear morphology associated with a staining by propid-
ium iodide (1 µg/ml) after the various treatments, indicat-
ing that almost no necrosis had occurred.
Electropherograms confirmed that MON cells did not
enter into apoptosis after exposure to CisPt (10 µM, for 2
h), etoposide (10 µM, for 2 h) or X-rays (5 Gy) over a
three-day period, but they did after UVC radiation (10–20
J/m2). In contrast, HeLa cells underwent DNA fragmenta-
tion typical of apoptosis after all the different treatments.
Representative gels are shown in Fig. 2A and 2B. These
various results indicate that although MON cells can
become apoptotic, they are much more resistant than
HeLa cells to the induction of apoptosis by a variety of
agents.
Cancers often show perturbation of signaling pathways
and over-expression of survival signals. Experiments were
therefore performed to determine whether wortmannin, a
PI3-K inhibitor, affected the apoptotic response of MON
cells to drug and radiation treatments. Cells were irradi-
ated with different doses of X-rays or treated with several
concentrations of vinblastine (an anticancer drug that
inhibits microtubule assembly by binding tubulin) or
wortmannin. These agents were employed separately or
together. Fig. 3A confirms that X-irradiation up to 8 Gy
did not induce any significant apoptosis in MON cells and
shows that wortmannin induced moderate apoptosis at
the concentrations used (up to 4 µM). However, when the
two agents were applied together, the resulting degree of
apoptosis was much greater than the addition of effects
produced by X-rays or wortmannin singly. A similar syn-
ergistic effect was produced when vinblastine and wort-
mannin were combined (Fig. 3B). Vinblastine alone at 8
nM induced a moderate apoptotic response in MON cells.
These findings suggest that inhibition of PI3-K may
increase the susceptibility of MON cells to potential apop-
totic stresses.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/11
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Induction of apoptosis assessed by fluorescence microscopy in HeLa and MON cells exposed for 2 h to CisPt and etoposide or  irradiated with X-rays and UVC Figure 1
Induction of apoptosis assessed by fluorescence microscopy in HeLa and MON cells exposed for 2 h to CisPt and etoposide or 
irradiated with X-rays and UVC. Cells, cultured and treated in Petriperm dishes, were stained with Hoechst 33342 and visual-
ized with an inverted epifluorescence microscope at different time intervals after the treatments. Cells with fragmented, mar-
ginated chromatin were defined as apoptotic. Quantitative analyses were performed by counting at least 1000 cells for each 
data point.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/11
Page 4 of 11
(page number not for citation purposes)
Analysis of internucleosomal DNA fragmentation Figure 2
Analysis of internucleosomal DNA fragmentation. A: Agarose gel electrophoresis of low molecular weight DNA extracted 
from HeLa and MON cells exposed for 2 h to 10 µM CisPt (P) or 10 µM etoposide (E) or irradiated with 5 Gy of X-rays (X) 
and harvested on consecutive days thereafter. C refers to untreated controls. B: Agarose gel electrophoresis of low molecular 
weight DNA extracted from HeLa and MON cells exposed to 5, 10 or 20 J/m2 UVC or not irradiated (0) and harvested on 
consecutive days thereafter. In A and B, low molecular weight DNA was extracted from 2.106 cells at each time and analyzed 
by electrophoresis through a 2% agarose gel. Sizes of DNA molecular weight standards are indicated. Gels shown are repre-
sentative of three separate experiments.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/11
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Induction of apoptosis assessed by fluorescence microscopy in MON cells following: Figure 3
Induction of apoptosis assessed by fluorescence microscopy in MON cells following:A) irradiation with X-rays at doses of 1 
(X1), 2 (X2), 4 (X4) or 8 Gy (X8), or continuous exposure to wortmannin at 0.5 (W0.5), 1 (W1), 2 (W2) or 4 µM (W4), or 
combined treatments with 1 Gy X-rays plus 0.5 µM wortmannin (X1+W0.5), 2 Gy X-rays plus 1 µM wortmannin (X2+W1), 4 
Gy X-rays plus 2 µM wortmannin (X4+W2) and 8 Gy X-rays plus 4 µM wortmannin (X8+W4).B) continuous exposure to vin-
blastine at 1 (V1), 2 (V2), 4 (V4) or 8 nM (V8), or to wortmannin at 0.5 (W0.5), 1 (W1), 2 (W2) or 4 µM (W4) or to the asso-
ciations 1 nM vinblastine plus 0.5 µM wortmannin (V1+W0.5), 2 nM vinblastine plus 1 µM wortmannin (V2+W1), 4 nM 
vinblastine plus 2 µM wortmannin (V4+W2) and 8 nM vinblastine plus 4 µM wortmannin (V8+W4). Cells, cultured and treated 
in Petriperm dishes, were stained with Hoechst 33342 and visualized with an inverted epifluorescence microscope 24 h after 
the beginning of the treatments. Fragmented, marginated chromatin defined apoptotic cells. Quantitative analyses were per-
formed by counting at least 1000 cells for each treatment. Data in each graph represent the means values ± standard deviations 
of two experiments.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/11
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Western blot analysis
Western blot analysis (Fig. 4) showed that p53, a key reg-
ulator of cell cycle check points and apoptosis after DNA
damage, was abundant in MON rhabdoid cells compared
to HeLa cells. Moreover, it accumulated more rapidly and
to a greater extent in the former than in the latter cells after
UVC irradiation and CisPt treatment. The accumulation
of p53 induced in MON cells by treatment with 40 µM
CisPt for 2 h was of the same order than that produced by
20 J/m2 of UVC. However, the cleavage of PARP, one of
the substrate of cysteines proteases activated during apop-
tosis, occurred in UVC-damaged MON cells but not fol-
lowing CisPt treatment. In HeLa cells the cleavage of PARP
was observed after both UVC and CisPt damage.
In Fig. 5, western blot analysis was done after challenging
MON cells with individual agents (X-rays, CisPt, vinblast-
ine, wortmannin) or with different combinations of
them. On the basis of the results in Fig. 3, analysis was
performed after 24 h of continuous treatment. p53 was
considerably upregulated by X-rays (4 Gy) and, as already
shown, by CisPt (4 µM), but also by the non genotoxic
agent vinblastine (8 nM). Wortmannin induced p53 pro-
tein only moderately at the concentrations used (2–4
µM). Combination of X-rays with wortmannin, CisPt or
Western blot analysis of p53 accumulation and PARP cleavage in HeLa and MON cells treated with 40 µM CisPt for 2 h or irra- diated with 20 J/m2 UVC and incubated for different time intervals before the sample processing Figure 4
Western blot analysis of p53 accumulation and PARP cleavage in HeLa and MON cells treated with 40 µM CisPt for 2 h or irra-
diated with 20 J/m2 UVC and incubated for different time intervals before the sample processing. These times (hours) were 
noted above the lanes. C refers to untreated controls. Lysates from 5.105 cells were subjected to SDS-PAGE (8%), blotted and 
incubated with a monoclonal antibody to p53 or PARP. The data are representative of two (PARP) to five (p53) independent 
experiments.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/11
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vinblastine, or of vinblastine with CisPt, resulted in higher
accumulation of p53 than that provoked by any agent
deployed separately. CisPt plus wortmannin, and vinblas-
tine plus wortmannin, induced p53 to similar or some-
what lower levels than those observed after exposure to
CisPt or vinblastine alone.
The downstream effectors p21WAF1/CIP and Mdm2 were
expressed in treated cells to an extent roughly correlating
with the amount of p53, except after treatment with X-rays
plus wortmannin or with vinblastine plus wortmannin,
which resulted in an induction of p21WAF1/CIP1 and of
Mdm2 much lower than that of p53.
The pro-apoptotic protein Bax, also normally under the
control of p53, was moderately induced by wortmannin
alone and by X-rays plus CisPt or vinblastine, but was not
significantly changed by vinblastine or CisPt alone or
most of the other combinations. After X-rays alone, the
amount of Bax was noticeably decreased. Its level was par-
tially restored when X-rays were combined with
Western blot analysis of relevant proteins involved in stress response and apoptosis in MON cells irradiated with 4 Gy of X- rays (X) or exposed to 2 (W2) or 4 µM wortmannin (W4), 8 nM vinblastine (V), 4 µM CisPt (Pt) or by the combined treat- ments 4 Gy X-rays plus 2 (X+W2) or 4 µM wortmannin (X+W4), 4 Gy X-rays plus 4 µM CisPt (X+Pt), 4 Gy X-rays plus 8 nM  vinblastine (X+V), 8 nM vinblastine plus 2 (V+W2) or 4 µM wortmannin (V+W4), 4 µM CisPt plus 2 (Pt+W2) or 4 µM wort- mannin (Pt+W4), and 4 µM CisPt plus 8 nM vinblastine (Pt+V) Figure 5
Western blot analysis of relevant proteins involved in stress response and apoptosis in MON cells irradiated with 4 Gy of X-
rays (X) or exposed to 2 (W2) or 4 µM wortmannin (W4), 8 nM vinblastine (V), 4 µM CisPt (Pt) or by the combined treat-
ments 4 Gy X-rays plus 2 (X+W2) or 4 µM wortmannin (X+W4), 4 Gy X-rays plus 4 µM CisPt (X+Pt), 4 Gy X-rays plus 8 nM 
vinblastine (X+V), 8 nM vinblastine plus 2 (V+W2) or 4 µM wortmannin (V+W4), 4 µM CisPt plus 2 (Pt+W2) or 4 µM wort-
mannin (Pt+W4), and 4 µM CisPt plus 8 nM vinblastine (Pt+V). C refers to the untreated control. Lysates from 5.105 cells were 
subjected to 7–14% gradient SDS-PAGE, blotted and incubated with the appropriate antibodies. The data are representative of 
two independent experiments.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/11
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wortmannin. The anti-apoptotic protein Bcl-2 showed a
moderate decrease following all treatments.
PARP cleavage, indicative of ongoing apoptosis, was
absent or very low in cells treated with X-rays, CisPt, or
wortmannin alone. Vinblastine employed alone (8 nM)
provoked moderate PARP cleavage. The combinations X-
rays plus CisPt, X-rays plus vinblastine, CisPt plus wort-
mannin, and CisPt plus vinblastine had little or no effect
on PARP integrity. In contrast, PARP cleavage was dramat-
ically increased in cells exposed to vinblastine plus wort-
mannin and X-rays plus wortmannin.
These results confirm that MON cells (a) may be resistant
to induction of apoptosis by genotoxic and stress signals,
and (b) show some disconnection between the stabiliza-
tion of p53 protein and the expression of some of its
downstream effectors on the one hand, and the cleavage
of PARP (i.e. apoptosis induction) on the other. This sug-
gests that these cells have dysfunctions in the p53 pathway
and apoptosis control. Also, western blot analysis, like-
wise morphological evaluation, indicates that the PI3-K
inhibitor wortmannin can sensitize MON cells to some
genotoxic and non-genotoxic treatments.
Cell growth inhibition assay
Finally, in order to establish whether the apoptosis-
related effects of the different treatments could be relevant
to MON cell proliferation, a cell growth inhibition assay
was performed. The effects of the agents, separately or in
combination, were evaluated after 72 h of treatment. The
dose-effect relationships showed that the IC50 values were
about 7.6 nM, 1.6 µM and 6.3 µM for vinblastine, CisPt
and wortmannin, respectively. Also, 2.5 Gy of X-rays
inhibited the proliferation of MON cells by 50%. The cor-
relation coefficients (r values) were 0.94 or greater, indi-
cating conformity of the data to the median-effect
principle and good reproducibility. For combinations of
pairs of agents, the combination index (CI) equation was
employed for determining synergistic, i. e. higher than
additive, and antagonistic, i. e. lower than additive,
effects. Table 1 shows that the combinations X-rays plus
wortmannin and vinblastine plus wortmannin inhibited
MON cell growth synergistically over a fairly wide range.
These same combinations had synergistic effects on the
induction of apoptosis (see above). In contrast, the com-
binations X-rays plus CisPt or vinblastine and CisPt plus
wortmannin or vinblastine, which were unable to trigger
apoptosis as judged by PARP cleavage, had marked antag-
onistic effects on the inhibition of growth of MON cells.
This was despite their damaging effects indicated by p53
accumulation (Fig. 5).
Discussion
MRTs combine aggressiveness and resistance to therapeu-
tic treatments and have a very discouraging prognosis. In
a search for factors responsible for the MRT phenotype,
some aspects of the apoptotic pathway were investigated
in MON rhabdoid cells. Normally, ATM and ATR, acti-
vated in response to DNA damage or stress, phosphorylate
p53 and block Mdm2, which targets p53 for destruction.
This results in increased levels and conformational
changes of p53 and subsequent suppression of prolifera-
tion by cell cycle arrest or apoptosis [reviewed in [23]].
The choice between these outcomes is dependent on the
extent of damage, as well as on environmental and intrin-
sic cellular factors. In the present study, comparison of
MON cells to HeLa cells revealed a particularly low sus-
ceptibility of MON cells to apoptosis following treatments
with several DNA damaging agents. Nevertheless, p53 was
abundant and was upregulated after treatment with all
genotoxic and non-genotoxic agents examined, singly and
in various combinations, whereas PARP cleavage did not
occur systematically. The lack of correlation between p53
Table 1: Variation of CIs at different effect levels
Treatment CI at ED50 CI at ED75 CI at ED90
X-rays + wortmannin + +++ +++
X-rays + CisPt - -- --
X-rays + vinblastine -- --- ----
Vinblastine + wortmannin ± +++ +++
CisPt + wortmannin -- --- ---
CisPt + vinblastine -- --- ----
CI < 1, = 1, and > 1 indicates synergism, additivity and antagonism, respectively. More precisely, symbols +, ++ and +++ describe slight synergism 
(CI between 0.85 and 0.90), moderate synergism (CI between 0.7 and 0.85) and synergism (CI between 0.3 and 0.7), respectively. Symbols -, --, --- 
and ---- indicate slight antagonism (CI between 1.10 and 1.20), moderate antagonism (CI between 1.20 and 1.45), antagonism (CI between 1.45 and 
3.3) and strong antagonism (CI > 3.3), respectively. Nearly additive effects (CI in the range 0.90 and 1.10) are represented by the symbol ±. ED50, 
ED75 and ED90 indicate 50%, 75% and 90% inhibition of growth, respectively. Equipotent amounts of the two agents were combined. In most exper-
iments employing X-rays, various ratios were tested. Each CI determination resulted from at least three independent experiments evaluating at 
least five different doses or dilutions of the two agents.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/11
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and cell death is illustrated by the fact that treatment of
cells with X-rays plus wortmannin, which leads to a mas-
sive destruction of PARP, resulted in an induction of p53
lower than that produced by X-rays plus CisPt, after which
no PARP cleavage was observed.
These observations indicate that rhabdoid cells may have
dysfunctions in the p53 pathway and in the control of
apoptosis, at least after some types of damage. In fact, the
transcription stimulating activity of p53, eliciting the
expression of responsive genes such as p21WAF1/CIP1and
Mdm2, appeared to be perturbed in treated MON cells.
That was the case after treatment of cells with X-rays plus
wortmannin and, especially, with vinblastine plus
wortmannin, which resulted in a lower induction of
p21WAF1/CIP1 and Mdm2 than expected on the basis of p53
accumulation. These treatments were able to drive cells
into apoptosis. Since p21WAF1/CIP1 blocks cell cycle pro-
gression through its negative activity on various cyclin
dependent kinases, it could be hypothesized that the rela-
tively reduced induction, or the diminution of p21WAF1/
CIP1, antagonizes the establishment of a secure G1 arrest
and thus facilitates apoptosis in these treated cells.
Anomalies in the control of apoptosis in MON cells are
probably also illustrated by the lack of positive correlation
between increase in the Bax/Bcl2 ratio and cell death.
Members of the Bcl-2 family normally interact to regulate
programmed cell death. Pro-apoptotic members of this
family include Bax, Bad etc. Bcl2 and others proteins act
as apoptotic inhibitors [reviewed in [24]]. In MON cells,
the Bax/Bcl2 balance did not appear to be a determining
factor for apoptotic outcome since, although this ratio
was increased by PARP-cleavage-stimulating treatments
(X-rays or vinblastine plus wortmannin), it was equally
enhanced in cells exposed to wortmannin alone, X-rays
plus CisPt, or CisPt plus vinblastine, after which no PARP
cleavage occurred.
The results also showed that the apoptotic outcome in
MON cells can be triggered by treatments combining the
PI3-K inhibitor wortmannin with another agent. Among
the Ras effector signaling pathways, the PI3-K/AKT path-
way facilitates G1 to S phase progression and plays a
major role in protecting cells from apoptosis by inhibiting
BAD and thus cytochrome C release, inactivating caspase-
9 and -3, and targeting p53 for destruction [25]. In MON
cells the apoptotic function of p53 is largely abrogated
possibly because the Ras signaling pathway, perhaps stim-
ulated by autocrine growth factors, generates an
antiapoptotic state that results in resistance to antineo-
plastic treatments. Wortmannin, by inhibiting the PI3-K,
may decrease the expression of survival factors such as
AKT. This is not sufficient to provoke apoptosis (wort-
mannin alone has little effect at the concentrations
tested). However, apoptosis is triggered in the presence of
other damage or stress signals such as X-rays (unable by
themselves to induce significant apoptosis in MON cells)
or vinblastine (moderately effective in provoking apopto-
sis at the concentration used). Nevertheless, inhibition
the PI3-K/AKT signaling pathway does not systematically
result in increased susceptibility to apoptosis after all
types of damage, as shown by the treatment combining
wortmannin and CisPt. The damage dependence of the
wortmannin effect has no clear explanation. It suggests a
complex crosstalk between survival factors, nature of
damage and apoptotic signals in MRT cells.
Interestingly, the synergistic effects on apoptosis of some
agent associations, such as wortmannin plus X-rays or vin-
blastine, are reflected in the inhibition of MON cell
growth. The considerable antagonistic effects of several
other combinations of CisPt, X-rays, vinblastin and wort-
mannin are also worth noting. The establishment of syn-
ergistic and antagonistic interactions between agents may
be relevant for future clinical choices of therapeutic
strategies.
Conclusions
In conclusion, these results obtained on a model cell line
suggest that perturbations of the p53 pathway and a
reduced apoptotic response in rhabdoid tumor cells
might contribute to the resistance of MRTs to antineoplas-
tic treatments. The Ras/PI3-K/AKT signaling pathway
seems to be involved in the dysfunctions induced in these
cells by the mutation in the hSNF5/INI1 gene and proba-
bly results in increased cell survival factors. Some combi-
nations that are synergistic or antagonistic towards the
inhibition of cell growth and the induction of apoptosis
have been identified and it is hoped that this approach
can provide some suggestions for new rational design of
therapeutic protocols.
Methods
Chemicals
CisPlatinium (II) diamine dichloride, etoposide, vinblas-
tine and wortmannin were purchased from Sigma-
Aldrich, St Quentin Fallavier, France. Stock solutions were
made in the appropriate solvents and stored in aliquots at
-20°C. Further dilutions were made in culture medium
immediately before use.
Irradiations
X-rays were delivered by a Philips MG 325 (Philips indus-
trial X-Ray, Hamburg, Germany) employed at 260 kV, 13
mA with a 0.5 mm Cu and 1 mm Al filter. The dose rate
was 1 Gy/min.
UVC: a Philips germicide tube was used with a maximal
emission at 254 nm. Cells were irradiated after removal ofCancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/11
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the culture medium from the plates. The dose rate was 0.5
J/m2/s. Doses given in this paper are incident doses.
Cell culture
The MRT cells MON [genetically characterized in ref. [6]],
generously supplied by O. Delattre (Institut Curie, Paris),
and HeLa cells were cultured as monolayers in RPMI-1640
supplemented with 10% fetal calf serum and 20 µg/ml
gentallin in a humidified 5% CO2 atmosphere at 37°C.
The cultures tested negative for mycoplasma species.
Cell growth inhibition assay
The physical and chemical agents were evaluated for their
effects separately and in pairs. After counting with a cell
counter (Beckman Coulter Inc., Palo Alto, CA, USA), 2.5
× 103 rhabdoid cells were seeded in 100 µl of medium in
96-well microtitre plates and incubated for 24 h at 37°
prior to adding the drugs or irradiating. The final volume
of medium, with or without drugs, was 200 µl per well
and incubation was continued for three days, which
ensured logarithmic growth of control cells throughout
the experiment. The effects of the treatments were deter-
mined in terms of growth inhibition by measuring the cel-
lular protein content according to the method of Skehan
et al. [26]. Cells were fixed with trichloroacetic acid and
then stained for 30 min. with 0.4% sulforhodamine B in
1% acetic acid. Unbound dye was removed by acetic acid
washes, and the protein-bound dye was extracted with
Tris base (pH 10) before determining its absorbance at
540 nm in a 96-well microplate reader Victor2
(PerkingElmer Life Siences, Boston, MA, USA).
Median-effect principle for dose-effect analysis
The multiple drug effect analysis of Chou and Talalay [27]
was used to calculate combined drug effects. Dose-effect
curves for each agent and for combinations, in multiply
diluted concentrations or scaled irradiation doses, were
plotted using the median-effect equation fa/fu = (D/
Dm)m, in which D is the dose, Dm is the dose required for
50% effect, fa is the fraction affected by dose D, fu is the
unaffected fraction and m is a coefficient of the sigmoidic-
ity of the dose-effect curve. The conformity of the data to
the median-effect principle was determined by the linear
correlation coefficient r. The combination index (CI)
equation for mutually non-exclusive drugs CI = (D)1/
(Dx)1 + (D)2/(Dx)2 + (D)1(D)2/(Dx)1(Dx)2, in which drug
1, (D)1, and drug 2, (D)2, in combination inhibit x%, and
(Dx)1 and (Dx)2 are the doses of drug 1 and drug 2 alone,
respectively, inhibiting x%, was employed for measuring
synergism and antagonism. CI < 1, = 1, and > 1 indicates
synergism, additive effect and antagonism, respectively.
Quantitations by computerized analysis [28] were done
using the Calcusyn software (Biosoft, Cambridge, UK).
Determination of apoptosis
Apoptosis was evaluated by both DNA fluorescence
microscopy of nuclear changes, as described elsewhere
[29], and DNA fragmentation analysis. For the latter, low
molecular weight DNA was extracted according to Her-
mann et al. [30] with minor modifications. At specific
times after treatment, non-adherent and adherent cells
were combined, rinsed with phosphate buffered saline
(PBS), counted and pelleted. Aliquots of 2.106cells were
lysed in 1% Nonidet P-40 (NP40) in 20 mM EDTA, 50
mM Tris-HCl (pH 7.5). After centrifugation for 5 min at
1,600 × g, the supernatant was collected and the extraction
repeated on the pellet. The supernatants were combined,
adjusted to 1% SDS and then treated for 2 h at 56°C with
RNAse A (final concentration, 1 µg/µl). Proteinase K was
added (final concentration, 1 µg/µl), and the mixture was
incubated for 2 h at 37°C. Ammonium acetate was then
added (final concentration, 1 M), and the DNA was pre-
cipitated by the addition of 2.5 volumes of ethanol and an
overnight incubation at -20°C. After centrifugation
(14,000 × g for 20 min at 4°C), the pellet was washed
with 70% ethanol, dissolved in 30 µl of gel-loading buffer
and separated by electrophoresis through a 2% agarose gel
using 40 mM Tris-acetate, 2 mM EDTA as running buffer.
DNA was visualized by ethidium bromide staining (1 µg/
ml) and photographed under UV illumination.
Western blot analysis
Whole-cell protein extracts were made from HeLa and
MON cells irradiated with UVC or X-rays or treated with
different compounds. At specific times after treatment,
non-adherent and adherent cells were collected, com-
bined, rinsed with PBS, counted and pelleted. Aliquots of
5.105 cells were lysed in RIPA buffer (50 mM Tris-HCl pH
7.5, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycho-
late, 0.1% SDS) containing 1 mM phenyl methyl sulfonyl
fluoride, 1 µg/ml aprotinin, 1 µg/ml pepstatin, 1 µg/ml
leupeptin and 50 mM Na fluoride for 30 min at 4 °C and
then boiled for 5 min. Alternatively, for PARP analysis,
cell pellets were resuspended in a defined volume of
reducing loading buffer (62.5 mM Tris-HCl pH 6.8, 6 M
urea, 10% glycerol, 2% SDS, 0.003% bromophenol blue,
5% 2-mercaptoethanol (freshly added)), sonicated on ice
with a cup horn tip to break DNA, and incubated for 15
min at 65°C. Proteins were separated by SDS-polyacryla-
mide gel electrophoresis (PAGE) and transferred on to
polyvinylidene fluoride membranes. Ponceau red staining
was performed to check that closely comparable amounts
of proteins had been loaded and transferred in each lane.
Immunoblots were incubated with the indicated primary
antibodies for 2 h at room temperature. Antibodies
against Mdm2 (SMP14, mouse monoclonal), Bcl-2 (100,
mouse monoclonal), Bax (P-19, goat polyclonal and B-9,
mouse monoclonal), p21WAF1/CIP1 (C-19, goat polyclonal
and F-5, mouse monoclonal) and p53 (DO-1, mousePublish with BioMed Central    and   every 
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monoclonal), were from Santa Cruz Biotechnology, Inc.
Santa Cruz, CA, USA. C2-10 mouse anti-PARP mono-
clonal antibody was from PharMingen International (Bec-
ton Dickinson, Grenoble, France). After washing, the
blots were incubated with the appropriate secondary anti-
bodies conjugated to horseradish peroxidase for 1 h at
room temperature, washed again and developed with an
enhanced chemiluminescence kit (Amersham Pharmacia
Biotech, Litle Chalfont, UK) according to the manufac-
turer's instructions.
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